In our study, the cumulated incidence rate of CNS metastases was 21.8% in HER2-positive tumours (compared with 11.1% in HER2-negative tumours), 32.5% in HR-negative tumours (compared with 9.2% in HR-positive tumours) and 32.7% in triple-negative tumours, respectively, consistent with previous literature data.37–39 HER2-positive, HR-negative and triple-negative tumours were reported respectively in 29.4%, 40.6% and 25.6% of patients with CNS metastases. The gene discussed is ERBB2; the disease is neoplasm.